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ABSTRACT
Background. Multidisciplinary cancer team meetings are
intended to optimize the diagnosis of a patient with a
malignancy. The aim of this study was to assess the number
of correct diagnoses formulated by the multidisciplinary
team (MDT) and whether MDT decisions were imple-
mented.
Methods. In a prospective study, data of consecutive
patients discussed at gastrointestinal oncology MDT
meetings were studied, and MDT diagnoses were validated
with pathology or follow-up. Factors of influence on the
correct diagnosis were identified by use of a Poisson
regression model. Electronic patient records were used to
assess whether MDT decisions were implemented, and
reasons to deviate from these decisions were hand-searched
within these records.
Results. In 74 MDT meetings, 551 patients were discussed
a total of 691 times. The MDTs formulated a correct
diagnosis for 515/551 patients (93.4 %), and for 120/551
(21.8 %) patients the MDT changed the referral diagnosis.
Of the MDT diagnoses, 451/515 (87.6 %) were validated
with pathology. Patients presented to the MDT by their
treating physician were 20 % more likely to receive a
correct diagnosis [relative risk (RR) 1.2, 95 % confidence
interval (CI) 1.1–1.5], while the number of patients dis-
cussed or the duration of the meeting had no influence on
this (RR 1.0, 95 % CI 0.99–1.0; RR 1.0, 95 % CI 0.9–1.1;
resp.). MDT decisions were implemented in 94.4 % of
cases. Deviations of MDT decisions occurred when a
patient’s wishes or physical condition were not taken into
account.
Conclusions. MDTs rectify 20 % of the referral diag-
noses. The presence of the treating physician is the most
important factor to ensure a correct diagnosis and adher-
ence to the treatment plan.
Multidisciplinary cancer team meetings are intended to
optimize the diagnosis for patients with malignancies,
thereby increasing the likelihood that patients will receive
the best possible care.1 A multidisciplinary team (MDT)
consists of healthcare professionals from different disci-
plines who offer their specific service and contribute to the
best care for each individual patient.2–4 MDTs have been
implemented worldwide to increase the quality of care;
however, the extent to which gastrointestinal oncology
MDTs actually improve the quality of care remains
undetermined.
In many other countries, including The Netherlands,
MDTs have become mandatory,3,5,6 which has made the
evaluation of the influence of MDTs on the quality of care
increasingly difficult. There is no comparable control group
for patients evaluated by an MDT, rendering randomized
controlled trials impossible. To assess the quality of MDTs,
different studies have suggested evaluating survival; how-
ever, these studies are likely subject to bias. When a
prospective intervention group is compared with an his-
torical cohort, differences in treatment over time may
influence results.1,6–8 Since the use of a prospective control
group is infeasible, it is difficult to determine the influence
of MDTs on the quality of care with a direct performance
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measure (e.g. survival). Instead, Kurpad et al. and Lamb
et al. suggested an indirect measure may be used to eval-
uate the impact of MDTs—the decision-making
process,1,4,9 which can be assessed using the number of
correct diagnoses formulated by the MDT.1,4,9–13
To date, studies describing MDTs or their decision-
making process do not relate to gastrointestinal malignan-
cies, are of retrospective design, or involve a subjective
evaluation by medical professionals.3,9,10,14,15 However,
some variables described in these studies can be used in a
prospective study, i.e. the presence of a chairperson, the
presence of the treating physician, the number of patients
discussed, time pressure, interruptions such as pagers fre-
quently ringing, and the presence of all necessary medical
specialties.2,4,16
To ensure that patients receive the best possible care, it
is not only important to assess whether the correct diag-
nosis is made but also to determine whether the MDT
decisions are implemented; approximately 18 % of MDT
decisions are not implemented.11 Understanding the rea-
sons for not implementing MDT decisions could improve
the quality of care and should also be taken into account
when studying the decision-making process of an
MDT.3,4,11,17
The primary objective of this study was to evaluate the
decision-making process of a gastrointestinal cancer MDT
at a tertiary referral center, together with factors influenc-
ing this process. Since time pressure is considered to be
very influential on the decision-making process, factors
influencing the duration of the MDTs and individual
patient discussions were also evaluated.2,4,16 The secondary
aim of this study was to evaluate whether MDT decisions
were implemented and which factors were responsible for
not implementing these decisions.
METHODS
Setting
This prospective study was conducted at a fast-track
clinic (FTC) for patients with (suspected) gastrointestinal
malignancies. The FTC is a tertiary referral center located
in a university hospital in The Netherlands. Four tumor-
specific MDT meetings are held from Monday to Thursday:
hepatocellular carcinoma (HCC), colorectal carcinoma
(CRC), esophageal and gastric cancer (ESOGAS) and
pancreatobiliary tumors (PB). Each meeting is attended by
a tumor-specific MDT consisting of specialized gastroin-
testinal cancer nurses and representatives from each
involved specialty (specialty physicians): surgery, gas-
troenterology, medical oncology, radiation oncology,
radiology, pathology, and nuclear medicine. After referral
by a medical specialist, imaging is re-reviewed by a spe-
cialized radiologist. If the imaging is missing or not current
enough, additional imaging is performed. The additional
imaging is performed before the MDT meeting, on the day
of the appointment. Pathology samples are requested after
each referral and are preferably assessed before the meet-
ing; however, since the waiting time to the FTC is 6 days
or less, pathology can be delayed.
New patients spend one full day at the FTC. In the
morning they are seen by the treating physician (either a
surgeon or gastroenterologist) who evaluates their symp-
toms and performance status. At noon, the tumor-specific
MDT convenes for a lunch meeting, and patients are
(preferably) presented by the treating physician. During
this meeting, the MDT either confirms or rectifies the
referral diagnosis and formulates a treatment plan for each
individual patient. All decisions made by the MDT are
documented ‘real-time’ in a shared electronic patient
record (EMR). The EMR is accessible to all specialty
physicians and the specialized nurses, enabling them to
consult the notes documented during the MDT meeting and
ensuring all convey the same information to the patient.
In the afternoon following the meeting, the treating
physician discusses the MDT diagnosis and treatment plan
with the patient. If a diagnosis or treatment plan cannot be
formulated during the MDT meeting, the patient is dis-
cussed again during a subsequent MDT meeting. For the
purpose of this study, these patients are defined as follow-
up patients. Generally, follow-up patients do not spend the
entire day at the FTC.
Data Collection
The decision-making process of the MDT was investi-
gated by assessing the number of correct diagnoses
formulated by the MDT, as well as the number of rectified
referral diagnoses. An independent researcher records the
MDT diagnosis during the meeting and compares this with
the referral diagnosis. Diagnoses formulated by the MDT
were validated either by pathology (preferred) or imaging
and laboratory results. Patients with a diagnosis not con-
firmed by pathology, or with a benign diagnosis, were
observed during follow-up. The variables recorded during
the meetings are documented in Table 1. Clinical data
gathered from the EMR included age, sex, MDT diagnosis
and stage, referral diagnosis, and pathology results.
The data of patients discussed at consecutive MDT
meetings were collected at two time intervals, with the first
interval being from December 2012 to March 2013. From
March to April 2013 a software upgrade was performed,
comprising a new form in the EMR to facilitate docu-
menting the decisions made by the MDT. Three months
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later, the form was adapted to increase user friendliness.
Although the same information was documented in both
forms, the new form differed in structure from the previous
form, and more input fields needed to be filled in, e.g.
additional input fields for the treating physician and the
chairperson, as opposed to one general input field. Since
this could potentially introduce a bias of the time mea-
surements of the patient discussions, no data were included
during this period.18 From September to December 2013,
data collection for the second interval took place. Patient
characteristics of the first and second periods were com-
pared using a Chi square test to evaluate the presence of
any differences and to ensure the two groups could be
analyzed as a single cohort.
Adherence to MDT decisions was assessed during fol-
low-up using all available information, e.g. charts, medical
letters. If treatment differed from the decision of the MDT,
hospital records where examined to determine why these
changes in the treatment plan were made.
Data Analysis
Statistical analysis was performed using SPSS version
21.0 software (IBM Corporation, Armonk, NY, USA). To
approximate the relative risk (RR) of a correct diagnosis at
the first MDT meeting, a multivariable modified Poisson
regression analysis was used. Included variables were
based on clinical relevance and were supported by litera-
ture (Table 1).2,4,16 With the Poisson analysis, the error for
the approximated RR can be overestimated; therefore, a
robust error variance procedure known as sandwich esti-
mation was used to obtain confidence intervals (CI).19 The
model was corrected for the different tumor-specific
MDTs.
To identify factors influencing the duration of the MDTs
and the discussion of the individual patient, two multi-
variate linear regression models were used. Included
variables were based on clinical relevance, supported by
literature (Table 1).2,4,16 Both models were corrected for
the differences between the various tumor-specific MDTs.
Ethics Committee Approval
Due to the observational nature of this study, the local
Medical Ethics Committee determined that formal
approval was not required.
RESULTS
Seventy-four gastrointestinal cancer MDT meetings
took place in 6 months, with a mean duration of 63 min
(SD ± 14). In total, 691 discussions took place for 551
new patients, of which 140/551 patients were discussed in
two or more MDT meetings. The mean discussion time per
new patient was 05:34 min (SD ± 2; 95 % CI 5:18–5:49),
and 4:20 min (SD 2.52; 95 % CI 4:00–4:41) per follow-up
patient. Patient characteristics were similar during both
time periods, with the exception of the number of HCC
patients discussed (Table 2).
The MDTs formulated a diagnosis for 545/551 patients
(Fig. 1). In 515/551 (93.5 %) patients, the MDT diagnosis
was correct, and 449/551 (81.5 %) of the diagnoses were
formulated at the first MDT meeting. In total, 87.8 %
(n = 451/545) of the diagnoses were validated with






(duration of patient discussion)
Presence/absence of the specialty physiciansa – ? ?
Presence of the treating physician ? – ?
Total number of people present – ? –
Presence of a chairperson ? ? ?
Number of interruptions during the meetingb ? – ?
Duration of the meeting ? ?c ?c
Duration of individual patient discussion (min) ? – –
Follow-up patient, yes or no – – ?
Total number of patients discussed ? ? –
Need for additional imaging ? – –
Change of referral diagnosis or treatment – – ?
a Including not only specialty physicians but also researchers, nurses, students, and residents
b Interruptions consisted of doctors arriving late or leaving early, and pagers ringing. ‘Late arrival’ was defined as arrival after the start of the
meeting or delaying the scheduled start of the meeting by more than 2 min
c Delay of the start of the meeting, in minutes
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pathology. In 64/545 patients (11.7 %) the diagnosis was
based solely on imaging and laboratory results, none of
which were changed during follow-up (median 9.0 months;
minimum–maximum: 0–35). For the 6/551 (1.1 %) patients
in whom the MDT could not formulate a diagnosis, addi-
tional biopsies and imaging were performed; however, still
no consensus could be reached and no treatment plan was
proposed. Of the 30/551 patients incorrectly diagnosed by
the MDT, 14/551 (2.5 %) had a benign diagnosis (chole-
cystitis, n = 4; pancreatitis, n = 3; gallstones, n = 1;
diverticulitis, n = 1; lipoma, n = 1; leiomyoma, n = 1;
hemangioma, n = 1; polyp, n = 2). For the remaining 16/
551 patients, a malignant diagnosis was formulated fol-
lowing pathological investigation (n = 7), surgery (n = 7),
or additional imaging (n = 2).
The MDT changed the referral diagnosis for 121/551
(22.0 %) patients. In one patient, the referral diagnosis was
incorrectly changed from esophageal to gastric cancer. Of
the 120/551 (21.8 %) patients with a rectified diagnosis, 11
patients were referred without a diagnosis, but with high
suspicion of malignancy. For two of these patients, the
MDT formulated a benign diagnosis. For the 109/120
patients referred with a diagnosis, both diagnosis and stage
were rectified for 17/551 (3.1 %) patients. Of these
patients, 14 initially diagnosed with localized disease were
reclassified to metastatic disease, and four patients referred
with metastatic disease were reclassified to localized dis-
ease. Stage alone was changed in 27/551 patients (4.9 %),
of which five patients referred with metastatic disease were
rediagnosed to have localized disease. Fifteen patients
initially diagnosed with localized disease were rediagnosed
to metastatic disease. The remaining seven patients had
more extensive metastatic disease than as diagnosed by the
referring physician. Diagnosis alone was rectified in 67/551
(12.2 %) patients. Of these patients, 33/551 (6.0 %) were
rediagnosed to benign disease (Fig. 2). Rectified diagnoses
were more often observed for patients discussed by the PB
MDT (32.9 %) compared with the other MDTs.
Following correction for the different MDT meetings,
the treating physician was the most influential factor to
ensure a correct diagnosis: patients were 20 % more likely
to receive a correct diagnosis (RR 1.2, 95 % CI 1.01–1.47).
Patients were less likely to be diagnosed correctly when
additional tests were needed after the MDT meeting
(RR 0.8, 95 % CI 0.76–0.93), and the number of patients
or the duration of the meeting did not influence this (95 %
CI 0.98–1.0) [Table 3]. The duration of a patient’s dis-
cussion increased when the MDT changed the referral
diagnosis (0:31 min/patient, 95 % CI 0:02–1:01), or when
a chairperson was present (1:14 min/patient, 95 % CI
0:32–1:24) [Table 4]. However, these variables did not
influence the probability of a correct diagnosis (95 % CI
0.98–1.01) [Table 3].
A treatment plan was formulated for 542 patients. Fif-
teen patients were excluded from analyses because it was
unclear what treatment they received (n = 6) or no treat-
ment plan was formulated (n = 9). Of the remaining
patients, 31/536 (5.8 %) received a different treatment than
advised by the MDT. Deviation occurred when patients’
wishes or physical condition were not taken into account:
15 patients preferred a different treatment or no treatment,
and 14 patients were physically unable to undergo the
preferred treatment, of which four patients died before
treatment could be initiated and four patients had







No. of patientsc 277 274
Age [years; mean (SD)] 63 (11.6) 66 (24.8) 0.24
Male [n (%)] 178 (64) 173 (63) 0.49
Second opinion 39 (14) 64 (23) 0.87
Diagnosis at first MDTM
[n (%)]
0.39
Correct diagnosis 238 (86) 240 (88)
Incorrect diagnosis 8 (3) 10 (4)
Treatment intent [n (%)] 0.26
Curative 105 (38) 123 (45)
Palliative 78 (28) 78 (29)
Unknown 72 (26) 56 (20)
Not applicable 22 (8) 17 (6)
Tumor-specific MDT [n (%)]
HCC 31 (11) 19 (7) 0.046
CRC 56 (20) 56 (20) 0.95
ESOGAS 74 (27) 87 (32) 0.19
PB 116 (42) 112 (41) 0.81
Time/MDTM [hours;
mean (SD)]
HCC 45:54 (16) 39:16 (7) 0.007
CRC 50:32 (12) 53:44 (17) 0.43
ESOGAS 63:00 (11) 62:00 (11) 0.13
PB 71:00 (7) 73:00 (9) 0.18
Time/patient [min; mean (SD)]
HCC 06:28 (2) 07:23 (3) 0.34
CRC 05:34 (2) 06:09 (3) 0.30
ESOGAS 05:32 (2) 05:09 (3) 0.40
PB 04:27 (1) 04:59 (2) 0.056
p values were calculated using a Chi square test
a First period: 27 December 2012 to 12 March 2013
b Second period: 24 September 2013 to 5 December 2013
c Only individual patients were considered in this table
HCC hepatocellular carcinoma, CRC colorectal carcinoma, ESOGAS
esophageal and gastric cancer, PB pancreatic and biliary tumors, SD
standard deviation, MDT multidisciplinary team, MDTM multidisci-
plinary team meeting
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progressed further than was assumed by the MDT. Treat-
ment for one patient changed after a second opinion from
another specialized oncology center, and two patients were
incorrectly diagnosed by the MDT. After their diagnosis
was corrected, these patients were treated accordingly.
DISCUSSION
This is the first study that has prospectively evaluated
how often MDTs formulate a correct diagnosis and the
factors that influence this. The value of a correct diagnosis
lies in the assumption that a correct diagnosis will lead to a
proper treatment plan, avoiding over- or under-treatment.4,
20 The present study shows that MDTs formulate a correct
diagnosis and stage for 94 % of the referred patients, and
the MDT rectified the referral diagnosis and stage in 22 %
of the evaluated patients. The presence of the treating
physicians was the most influential variable to ensure a
correct diagnosis.
MDTs are increasingly initiated in order to, ultimately,
improve patient outcomes.1,4,15,21,22 The development of
multimodal treatments further emphasizes the need for a
multidisciplinary approach. Although it may seem
unquestionable that MDTs have a positive effect on the
patient outcomes, this remains difficult to evaluate.4,9,15




















- Cholangiocarcinoma (3x) with livermetasis (1x)
- HCC






- Pancreatic head cancer
FIG. 2 Changes in referral diagnosis. Of the 551 patients referred,
the MDT diagnosis was the same as the referral diagnosis in 431
patients. Eleven patients were referred without a diagnosis, and the
MDT diagnosed all these patients; three were diagnosed with a
cholangiocarcinoma, of which one patient also had liver metastasis,
two patients had a benign diagnosis, and the remaining six patients
had various malignancies. Patients referred without a diagnosis were
suspected of having a malignancy. For 67 patients the diagnosis alone
was changed; of these patients, 33 had a benign diagnosis. Dx
diagnosis, M± change in staging of disease, MDT multidisciplinary
team




















• Mammacarcinoma with 
pancreasmetastasis (not validated ) (n=1)
• Pancreatic cancer (not validated ) (n=1)*
• Liver tumor (malignant), no classifying
pathology after autopsy (n=1)
• Cholecystitis (n=1)
• Pancreatichead carcinoma with
livermetastasis (n=1)
• Oesophagealcancer with lung and
livermetastasis (n=1)
Diagnosis formulated after meeting
FIG. 1 Diagnoses formulated
by the MDT. In total, the MDT
formulated a diagnosis for 545
patients—515 (93.5 %) accurate
diagnoses, of which 451 were
validated with pathology, and 30
inaccurate diagnoses. The MDT
formulated a new diagnosis for
these patients after review of
additional information.
Eventually, 14 patients who had
previously received a malignant
diagnosis turned out to have
benign disease. *Diagnosis
uncertain and treatment never
initiated. MDT multidisciplinary
team
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TABLE 4 Linear regression model of variables influencing duration
Variable Influence on duration (min) 95 % CI p value
Duration of MDTM
Patients 2:20 1:29 to 3:10 \0.001
Interruptionsa 0:14 0:03 to 0:26 0.015
Minutes late starting meeting -0:53 -2:10 to 0:22 0.16
Absence of medical specialist 3:24 -1:48 to 8:37 0.19
Presence of chairperson 0:57 -4:19 to 6:14 0.71
Total physicians present 0:54 0:02 to 1:46 0.042
Total non-physicians present -0:07 -1:46 to 0:56 0.79
Tumor type
HCC Reference group
CRC 1:51 -4:32 to 8:15 0.56
ESOGAS 0:52 -5:30 to 7:14 0.78
PB 4:34 -4:49 to 3:58 0.33
Time per patientb
Follow-up patient -1:47 -2:10 to -1:18 \0.001
Interruptions -0:03 -0:07 to 0:10 0.16
Minutes late starting meeting 0:05 -0:01 to 0:12 0.090
Presence of chairperson 0:35 0:08 to 1:03 0.010
Treating physician -0:07 -0:58 to 0:44 0.59
Absence of medical specialist -0:03 -0:30 to 0:21 0.81
Changing diagnosis 0:28 0:02 to 1:01 0.056
Changing treatment 1:14 0:32 to 1:24 0.001
Tumor type
HCC Reference group
CRC -1:31 -2:18 to -0:38 0.001
ESOGAS -1:36 -2:21 to -0:46 \0.001
PB -2:38 -3:21 to -1:51 \0.001
Linear regression model. The variable ‘Treating physician’ indicates whether the treating physician has presented the patient to the MDT (yes or
no)
a Interruptions per minute, corrected for total duration of MDTM
b All patients included
CI confidence interval, MDT multidisciplinary team, MDTM multidisciplinary team meeting, HCC hepatocellular carcinoma, CRC colorectal
carcinoma, ESOGAS esophageal and gastric cancer, PB pancreatic and biliary tumors
TABLE 3 Poisson analyses of variables influencing correct diagnosis
Variable RR 95 % CI p value
Treating physician (yes) 1.2 1.02–1.47 0.046
Duration of patient discussion 1.0 0.98–1.00 0.24
Duration of MDTM 1.0 0.99–1.00 0.26
Additional tests needed (yes) 0.8 0.76–0.93 \0.001
Presence of chairperson (yes) 1.0 0.97–0.10 0.31
Total number of patients 1.0 0.98–1.01 0.29
Interruptions 1.0 0.99–1.01 0.67
Multivariable analysis with modified Poisson regression to estimate the RR
The variable ‘Treating physician (yes)’ indicates that the treating physician has presented the patient to the MDT; the variable ‘Additional tests
needed (yes)’ indicates the need for additional tests; and the variable ‘Presence of chairperson (yes)’ indicates a chairperson was present
RR relative risk, CI confidence interval, MDT multidisciplinary team, MDTM multidisciplinary team meeting
Corrected for tumor-specific MDTs
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healthcare outcomes and the fact MDTs have become
mandatory in many Western countries, limiting the use of a
prospective control group.3,5,6,15 Three studies from the
Johns Hopkins 1-day diagnostic clinic in the US tried to
evaluate the effect of MDTs by determining how often
referral diagnoses and treatment plans are altered after
evaluation by a specialized MDT.15,22,23 The study by
Pawlik et al. had a prospective design and found that a
pancreas cancer MDT altered the initial diagnosis in
22.2 % of evaluated cases.23 The retrospective design
study by Zhang et al. observed that the MDT of a spe-
cialized liver clinic altered the diagnosis in 18.4 % of
evaluated cases,22 while the study by Sundi et al. also had a
retrospective design. These investigators found that 28.7 %
of men referred with prostate cancer had a change in their
risk category or stage.15 Most of the altered diagnoses
described in these studies were formulated after re-review
of imaging and pathology, or new findings resulting from
additional diagnostic tests. Although these studies report
the changes in referral diagnoses, they do not explicitly
report if the diagnosis was correctly changed, nor do they
report variables of influence on formulating an accurate
diagnosis.15,22,23
Some literature on the variables of influence on decision
making of MDTs is available; however, these factors have
not been previously studied for gastrointestinal cancer
MDTs. In a review of the literature, Lamb et al. noticed
that the treating physician contributes to an improved
decision-making process,12 and the present study con-
firmed this. The presence of a treating physician with pre-
existing knowledge of the patient increases the probability
of a correct diagnosis (RR 1.2). This physician is also most
likely to know the patients’ wishes and ensures an indi-
vidualized treatment plan, emphasizing the importance of
his presence. In a single case study design studying a large
gynecology cancer MDT, Lanceley et al. found that time
pressure, absence of medical specialists, and lack of lead-
ership negatively influenced the decision-making
process.13 Unexpectedly, in this study the duration of the
MDT meeting and the number of patients discussed (per-
ceived time pressure) did not seem to influence the
probability of a correct diagnosis. Furthermore, our results
did not show that the presence of a chairperson or the
absence of a medical specialist influenced the probability
of a correct diagnosis; however, we feel it is important to
stress that an MDT will likely function better when all
involved specialty physicians required to diagnose the
patient are present.11,17
Limitations
The number of variables included in a linear or logistic
regression model is restricted to the number of events
divided by 10. The MDT did not formulate a (correct)
diagnosis at the first meeting for 66 patients, restricting the
number of variables to six or seven. Factors of influence of
the decision-making process could have been missed by
this restriction. Of the evaluated patients, 22 % received a
different diagnosis by the MDT; however, due to the
selected patient group, it is unclear how these results can be
extrapolated to other MDTs for either different malignan-
cies or benign diseases. It is possible the effect of MDTs is
greatest for patients with complex disease, such as gas-
trointestinal malignancies. Furthermore, for many of the
referrals it was unclear whether the referral diagnosis was
formulated by an individual physician or a (less special-
ized) MDT. This can potentially create a bias in our results.
CONCLUSIONS
The evidence proving the added value of MDTs in
cancer care is growing and the results of this study further
endorse this hypothesis. To improve the quality of MDTs,
adequate documentation of decisions made by the MDT
accessible by all involved physicians and nurses is needed.
This not only improves communication between different
specialties but also ensures all physicians convey the same
MDT advice to the patient. In our opinion, a shared EMR is
necessary for a well-functioning MDT, and both current
and future EMRs should incorporate this. However, the
most influential variable to ensure an accurate diagnosis
and to take into account both patient preferences and per-
formance state is relatively simple and can easily be
extrapolated to MDTs in other countries. Every patient
discussed by an MDT should be presented by a physician
who has seen and talked to the patient.
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